Investigating rutin as a potential transforming growth factor‐β type I receptor antagonist for the inhibition of bleomycin‐induced lung fibrosis
BioFactors · 2024
DOI: 10.1002/biof.2020 ↗At a glance
Journal article in BioFactors, 2024. Written by Wisurumuni Arachchilage Hasitha Maduranga Karunarathne and 6 co-authors. Institution: Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea. Major MEDLINE topics: Bleomycin, Pulmonary Fibrosis, Receptor, Transforming Growth Factor-beta Type I, Rutin. Cited 14 times so far (Crossref); 63 references. Funded by: Korea Environmental Industry and Technology Institute, National Research Foundation of Korea.
Abstract (original language)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition characterized by the abnormal regulation of extracellular matrix (ECM) and epithelial‐mesenchymal transition (EMT). In this study, we investigated the potential of rutin, a natural flavonoid, in attenuating transforming growth factor‐β (TGF‐β)‐induced ECM regulation and EMT through the inhibition of the TGF‐β type I receptor (TβRI)‐mediated suppressor of mothers against decapentaplegic (SMAD) signaling pathway. We found that non‐toxic concentrations of rutin attenuated TGF‐β‐induced ECM‐related genes, including fibronectin, elastin, collagen 1 type 1, and TGF‐β , as well as myoblast differentiation from MRC‐5 lung fibroblast cells accompanied by the downregulation of α‐smooth muscle actin. Rutin also inhibited TGF‐β‐induced EMT processes, such as wound healing, migration, and invasion by regulating EMT‐related gene expression. Additionally, rutin attenuated bleomycin‐induced lung fibrosis in mice, thus providing a potential therapeutic option for IPF. The molecular docking analyses in this study predict that rutin occludes the active site of TβRI and inhibits SMAD‐mediated fibrotic signaling pathways in lung fibrosis. These findings highlight the potential of rutin as a promising anti‐fibrotic prodrug for lung fibrosis and other TGF‐β‐induced fibrotic and cancer‐related diseases; however, further studies are required to validate its safety and effectiveness in other experimental models.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea.
- Department of Biosystems Technology, Faculty of Technology, University of Ruhuna, Matara, Sri Lanka.
- Forest Bioresources Department, Forest Microbiology Division, National Institute of Forest Science, Suwon, Republic of Korea.
- Department of Biochemistry, College of Korean Medicine, Dong-Eui University, Busan, Republic of Korea.
- Nakdonggang National Institute of Biological Resources, Sangju, Republic of Korea.
- Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, USA.
ORCID profiles: Gi-Young Kim
Funding
- Korea Environmental Industry and Technology Institute
- National Research Foundation of Korea
Cite
APA
Karunarathne, W. A. H. M., Lee, K. T., Choi, Y. H., Kang, C. H., Lee, M. H., Kim, S. H., & Kim, G. Y. (2024). Investigating rutin as a potential transforming growth factor‐β type I receptor antagonist for the inhibition of bleomycin‐induced lung fibrosis. BioFactors. https://doi.org/10.1002/biof.2020
Vancouver
Karunarathne WAHM, Lee KT, Choi YH, Kang CH, Lee MH, Kim SH, et al. Investigating rutin as a potential transforming growth factor‐β type I receptor antagonist for the inhibition of bleomycin‐induced lung fibrosis. BioFactors. 2024. doi:10.1002/biof.2020
BibTeX
@article{Karunarathne2024,
author = {Karunarathne, Wisurumuni Arachchilage Hasitha Maduranga and Lee, Kyoung Tae and Choi, Yung Hyun and Kang, Chang-Hee and Lee, Mi-Hwa and Kim, Sang-Hun and Kim, Gi-Young},
title = {Investigating rutin as a potential transforming growth factor‐β type I receptor antagonist for the inhibition of bleomycin‐induced lung fibrosis},
journal = {BioFactors},
year = {2024},
doi = {10.1002/biof.2020}
}
EUVIMED